Mira Pharmaceuticals Inc (MIRA)

$1.48 +0.04 (2.78%)
Market Cap 60.30M
Revenue (ttm) 0.00
Net Income (ttm) -7.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 174,900
Avg Vol 3,704,672
Day's Range N/A - N/A
Shares Out 41.88M
Stochastic %K 65%
Beta 1.79
Analysts Sell
Price Target $11.00

Company Profile

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic st...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 786-432-9792
Address:
1200 Brickell Avenue, Suite 1950 #1183, Miami, United States
Jaespresso
Jaespresso Dec. 4 at 9:18 PM
$MIRA
0 · Reply
MREricPirate
MREricPirate Dec. 4 at 8:46 PM
$MIRA damn it hit the wall at 1.49
0 · Reply
Stockmarine
Stockmarine Dec. 4 at 6:26 PM
$MIRA guess we didn't get the november boom, here's for December !
0 · Reply
RaphaelRapoport
RaphaelRapoport Dec. 4 at 12:26 PM
$MIRA We need one big 10% day and this will be beautiful positioning for heavy loading. Let's go baby!
0 · Reply
Jaespresso
Jaespresso Dec. 3 at 2:57 PM
$MIRA
0 · Reply
dover20
dover20 Dec. 2 at 7:08 PM
$MIRA
0 · Reply
Buder
Buder Dec. 2 at 4:42 PM
$MIRA bullish
0 · Reply
Jaespresso
Jaespresso Dec. 2 at 2:47 PM
$MIRA
0 · Reply
Jawu
Jawu Dec. 2 at 10:50 AM
$MIRA earnings tomorrow?!?
1 · Reply
RaphaelRapoport
RaphaelRapoport Dec. 1 at 12:20 PM
$MIRA Can't wait for news to release and bring this baddie back up towards $2. We had a merger which valued this company at a combined value of close to $3. With the MAD results coming positive we should be seeing this fly. It's only a matter of time gentleman. Load up now before the run comes.
0 · Reply
Latest News on MIRA
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Oct 24, 2025, 7:30 AM EDT - 5 weeks ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Oct 16, 2025, 7:30 AM EDT - 7 weeks ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Sep 30, 2025, 7:30 AM EDT - 2 months ago

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Sep 22, 2025, 8:00 AM EDT - 2 months ago

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Sep 16, 2025, 7:30 AM EDT - 2 months ago

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

Sep 12, 2025, 7:30 AM EDT - 2 months ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Aug 19, 2025, 8:30 AM EDT - 3 months ago

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

Aug 12, 2025, 8:30 AM EDT - 4 months ago

MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

Jul 30, 2025, 7:30 AM EDT - 4 months ago

MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

Jul 29, 2025, 7:30 AM EDT - 4 months ago

MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

Jul 11, 2025, 8:00 AM EDT - 5 months ago

MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

Jul 3, 2025, 8:00 AM EDT - 5 months ago

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

Jun 30, 2025, 8:00 AM EDT - 5 months ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

Jun 25, 2025, 8:00 AM EDT - 5 months ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

Jun 18, 2025, 8:30 AM EDT - 6 months ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

May 28, 2025, 8:30 AM EDT - 6 months ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

May 8, 2025, 8:00 AM EDT - 7 months ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

May 6, 2025, 8:00 AM EDT - 7 months ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

Apr 23, 2025, 8:00 AM EDT - 8 months ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

Apr 16, 2025, 8:00 AM EDT - 8 months ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

Apr 1, 2025, 8:00 AM EDT - 8 months ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Mar 24, 2025, 7:30 AM EDT - 9 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

Mar 13, 2025, 8:00 AM EDT - 9 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Mar 4, 2025, 8:00 AM EST - 9 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

Dec 19, 2024, 9:00 AM EST - 1 year ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Dec 10, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Nov 20, 2024, 7:44 AM EST - 1 year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Oct 28, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

Oct 21, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Sep 27, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

Sep 18, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

Sep 11, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

Aug 26, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

Aug 19, 2024, 7:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

Aug 12, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

Jul 25, 2024, 7:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

Jul 22, 2024, 2:33 PM EDT - 1 year ago

S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Jul 22, 2024, 8:00 AM EDT - 1 year ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Jun 24, 2024, 8:30 AM EDT - 1 year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA Announces Positive Test Results

Jun 17, 2024, 2:07 PM EDT - 1 year ago

MIRA Announces Positive Test Results

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

May 29, 2024, 8:45 AM EDT - 1 year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 21, 2024, 8:45 AM EDT - 1 year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

May 20, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Mar 21, 2024, 11:04 AM EDT - 1 year ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

MIRA Pharmaceuticals Provides Corporate Update

Feb 5, 2024, 8:30 AM EST - 1 year ago

MIRA Pharmaceuticals Provides Corporate Update

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

Dec 4, 2023, 8:00 AM EST - 2 years ago

MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Nov 29, 2023, 8:00 AM EST - 2 years ago

MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%

Jaespresso
Jaespresso Dec. 4 at 9:18 PM
$MIRA
0 · Reply
MREricPirate
MREricPirate Dec. 4 at 8:46 PM
$MIRA damn it hit the wall at 1.49
0 · Reply
Stockmarine
Stockmarine Dec. 4 at 6:26 PM
$MIRA guess we didn't get the november boom, here's for December !
0 · Reply
RaphaelRapoport
RaphaelRapoport Dec. 4 at 12:26 PM
$MIRA We need one big 10% day and this will be beautiful positioning for heavy loading. Let's go baby!
0 · Reply
Jaespresso
Jaespresso Dec. 3 at 2:57 PM
$MIRA
0 · Reply
dover20
dover20 Dec. 2 at 7:08 PM
$MIRA
0 · Reply
Buder
Buder Dec. 2 at 4:42 PM
$MIRA bullish
0 · Reply
Jaespresso
Jaespresso Dec. 2 at 2:47 PM
$MIRA
0 · Reply
Jawu
Jawu Dec. 2 at 10:50 AM
$MIRA earnings tomorrow?!?
1 · Reply
RaphaelRapoport
RaphaelRapoport Dec. 1 at 12:20 PM
$MIRA Can't wait for news to release and bring this baddie back up towards $2. We had a merger which valued this company at a combined value of close to $3. With the MAD results coming positive we should be seeing this fly. It's only a matter of time gentleman. Load up now before the run comes.
0 · Reply
OGTDeepWaters
OGTDeepWaters Nov. 30 at 5:54 PM
$MIRA Every now and then this one pumps, you know what to do if it does, early stage, burns cash, high valuation, for the forseeable future into late next year a good fade off squeezes.
0 · Reply
Jaespresso
Jaespresso Nov. 28 at 3:14 PM
$MIRA
0 · Reply
KPW963
KPW963 Nov. 28 at 2:31 PM
$MIRA
0 · Reply
5880dovet
5880dovet Nov. 27 at 3:47 AM
$MIRA - He wants to fast track treatments for PTSD .
0 · Reply
Robert345
Robert345 Nov. 26 at 4:47 PM
$MIRA
0 · Reply
retirementsoon2
retirementsoon2 Nov. 26 at 3:29 PM
$MIRA
0 · Reply
Moobumples
Moobumples Nov. 26 at 1:22 PM
$MIRA due to the safety and efficacy of the SAD trial with Mira’s ketamir 2, and MAD being 3 cohorts - we could be hearing news about the MAD phase any day now. If it continues its uptrend and is successful, Ketamir-2 passes the MAD phase which will lead to phase 2. You will never see Mira at this early price again. Big investors normally enter at MAD succession prior to phase 2. This is only for Mira’s ketamir 2, we haven’t even talked about Mira’s “Mira 55” which outperformed morphine in animal trials. (Still early though) Good luck to those who hold and believe, Happy Thanksgiving 🦃
1 · Reply
MrWolf19
MrWolf19 Nov. 26 at 11:44 AM
$MIRA
0 · Reply
Gev222
Gev222 Nov. 25 at 11:06 PM
$MIRA
0 · Reply
Jaespresso
Jaespresso Nov. 25 at 8:56 PM
$MIRA
0 · Reply
Vcass1
Vcass1 Nov. 25 at 4:11 PM
$MIRA Very bullish
0 · Reply
retirementsoon2
retirementsoon2 Nov. 25 at 3:43 PM
$MIRA
1 · Reply